Epidemiology and host- and variety-dependent characteristics of infection due to Cryptococcus neoformans in Australia and New Zealand

Clinical Infectious Diseases

Volumn 31, Issue 2, 2000, Pages 499-508

  Chen, Sharon ^a   Sorrell, Tania ^a   Nimmo, Graeme ^b   Speed, Bryan ^c   Currie, Bart ^d   Ellis, David ^e   Marriott, Deborah ^f   Pfeiffer, Tania ^e   Parr, Dinah ^g   Byth, Karen ^h  

^a WESTMEAD HOSPITAL   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c AUSTIN HEALTH   (Australia)

^d MENZIES SCHOOL OF HEALTH RESEARCH   (Australia)

^e WOMEN S AND CHILDREN S HOSPITAL   (Australia)

^f ST VINCENT S HOSPITAL   (Australia)

^g AUCKLAND CITY HOSPITAL   (New Zealand)

^h Westmead Institute for Cancer Research   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; AUSTRALIA; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; IMMUNE DEFICIENCY; IMMUNE STATUS; INFANT; LUNG TUMOR; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; PRIORITY JOURNAL; PROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIFUNGAL AGENTS; AUSTRALIA; CHILD; CHILD, PRESCHOOL; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; FEMALE; HUMANS; IMMUNOCOMPROMISED HOST; INFANT; INFANT, NEWBORN; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEW ZEALAND; PROSPECTIVE STUDIES; RANDOM AMPLIFIED POLYMORPHIC DNA TECHNIQUE;

EID: 0034457941     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/313992     Document Type: Article

References (41)

1. Cryptococcosis
2. Clinical and hosts differences between infections with the two varieties of C. Neoformans
3. Cryptococcal disease of the CNS in immunocompetent hosts: Influence of cryptococcal variety on clinical manifestations and outcome
4. Correct predictors of outcome in Cryptococcus neoformans var. Gattii meningitis
5. Clinical epidemiological study of 171 cases of cryptococcosis
6. The ecology of Cryptococcus neoformans
7. Epidemiology of cryptococcosis in France: A 9-year survey (1885-1993)
8. Cryptococcosis: Population-based multistate active surveillance and risk factors in human immunodeficiency virus-infected persons
9. Estimation of the prevalence of cryptococcal infection among HIV-infected individuals in New York City
10. Decline in the incidence of cryptococcosis among HIV-infected patients
11. The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs
12. Update: Trends in AIDS incidence, deaths and prevalence - United States, 1996
13. DNA probes for strain typing of Cryptococcus neoformans
14. Molecular subtype distribution of Cryptococcus neoformans in four areas of the United States
15. Concordance of clinical and environmental isolates of Cryptococcus neoformans var. Gattii by random amplification of polymorphic DNA and PCR fingerprinting
16. Identification by random amplification of polymorphic DNA of a common molecular type of Cryptococcus neoformans var. Neoformans in patients with AIDS or other immunosuppressive conditions
17. Glossary of terms for thoracic radiology: Recommendations of the nomenclature committee of the Fleischner Society
18. Improved diagnostic medium for separation of Cryptococcus neoformans var. Neoformans (serotypes A and D) and Cryptococcus neoformans var. Gattii (serotypes B and C)
19. Susceptibility testing of Cryptococcus neoformans: A microdilution technique
20. The development of amphotericin B resistant Cryptococcus neoformans during treatment in an Australian HIV-infected patient
21. Serotypes of Australian environmental and clinical isolates of Cryptococcus neoformans
22. Cryptococcal meningitis in Durban, South Africa: A comparison of clinical features, laboratory findings, and outcome for human immunodeficiency virus (HIV)-positive and HIV-negative patients
23. Cryptococcus neoformans in tropical northern Australia: Predominantly variant gattii with good outcomes
24. Isolation of Cryptococcus neoformans var. Gattii from Eucalyptus camaldulensis in India
25. First isolation of Cryptococcus neoformans var. Gattii in Apulia, Italy
26. Cryptococcal meningitis. A review of 32 years' experience
27. Exposure to Cryptococcus neoformans var. Gattii: A seroepidemiological survey
28. Decreased resistance to primary intravenous Cryptoccocus neoformans infection in aged mice despite adequate resistance to intravenous challenge
29. Pathology of cryptococcal meningoencephalitis: Analysis of 27 patients with pathogenetic implications
30. Catecholamine oxidative products, but not melanin, are produced by Cryptococcus neoformans during neuropathogenesis in mice
31. Amphotericin B resistant Cryptococcus neoformans in a patient with AIDS